

# Brief mobile app-based intervention for non-suicidal self-injury

<b>Submission date</b> 22/02/2025	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered
		<input checked="" type="checkbox"/> Protocol
<b>Registration date</b> 13/03/2025	<b>Overall study status</b> Ongoing	<input type="checkbox"/> Statistical analysis plan
		<input type="checkbox"/> Results
<b>Last Edited</b> 28/01/2026	<b>Condition category</b> Injury, Occupational Diseases, Poisoning	<input type="checkbox"/> Individual participant data
		<input checked="" type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Non-suicidal self-injury behaviors (NSSI), like self-cutting, are becoming more common among adolescents and young adults worldwide. Although these behaviors are not intended to be suicidal, they are a significant risk factor for suicide and cause emotional distress for those affected and their families. NSSI is increasingly seen in the general population, making it a public health concern. Current treatments for NSSI are often expensive and hard to access. This study aims to develop a mobile phone app to provide an accessible treatment for NSSI, helping young people manage their self-injury and improve their emotional well-being.

### Who can participate?

Young people aged 14 to 24 years who are dealing with mental health issues and NSSI can participate in the study.

### What does the study involve?

Participants will first answer online questions about their clinical symptoms and NSSI behavior. Then, 300 participants will be selected for the second phase. Some of these participants will undergo brain scans to see how their brain processes physical and emotional pain. Over the next 5 weeks, one group will use the NSSI-specific app, while another group will use a different app not tailored for NSSI. This will help determine if the NSSI-specific app is effective.

### What are the possible benefits and risks of participating?

Participants may benefit from the app-based intervention, which could help them manage NSSI and improve their emotional well-being. There are minimal risks, mainly related to the discomfort of answering personal questions and undergoing brain scans.

### Where is the study run from?

Hospital Universitari de Bellvitge (Spain)

### When is the study starting and how long is it expected to run for?

December 2022 to October 2026

Who is funding the study?  
Fundació la Marató de TV3 (Spain)

Who is the main contact?  
Daniel Vega, daniel.vegamo@gmail.com

## Contact information

### Type(s)

Public, Scientific, Principal investigator

### Contact name

Mr Daniel Vega

### ORCID ID

<https://orcid.org/0000-0002-5621-8987>

### Contact details

Consorci Sanitari de l'Anoia  
Av. Catalunya 11  
Igualada  
Spain  
08700  
+34-938075500  
recerca@fsigualada.org

## Additional identifiers

### Clinical Trials Information System (CTIS)

Nil known

### Protocol serial number

La MArató 202233-30-31-32-33

## Study information

### Scientific Title

Design and analysis of the effectiveness of a brief mobile App-based intervention for Non-Suicidal Self-Injury: self-report, momentary and biological predictors of treatment outcomes

### Acronym

KALMER-NSSI

### Study objectives

- Hypothesis 1: We hypothesized that participants receiving a mobile App-based brief intervention for NSSI, will show a greater improvement of well-being and quality of life at the end of the treatment and at follow-up compared to participant receiving a non-specific App-based intervention.
- Hypothesis 2: Compared to healthy participants, youth with NSSI will report less physical pain

intensity and unpleasantness in response to the same noxious pressure and higher distress during the social rejection task. Youth with NSSI will show reduced physical pain-evoked responses in the Neurologic Pain Signature in response to the same peripheral noxious input (same pressure) and similar brain marker responses when subjective pain is matched across groups. We anticipate significantly augmented rejection brain marker responses in response to social rejection in line with anticipated increases in ratings of affective distress for the NSSI group (vs. healthy peers).

- Hypothesis 3: In youth with NSSI, pairing social rejection with physical pain will evoke greater reductions in affective distress ratings compared with healthy peers and will lead to greater reductions in rejection brain marker responses while increasing activation in the reward system. Conversely, in NSSI patients (vs. healthy), handholding during social rejection will lead to less pronounced reductions in the rejection brain signature, less activation of the reward system, and less reduction in ratings of affective distress.

- Hypothesis 4: We anticipate that brain activity in medial and lateral PFC and ventral striatal reward circuitry will predict responses to App-based treatment.

### **Ethics approval required**

Ethics approval required

### **Ethics approval(s)**

approved 12/12/2022, Research Ethics Committee of Bellvitge University Hospital (Hospital Universitari de Bellvitge, L'Hospitalet de Llobregat, Barcelona, 08907, Spain; +34-932607500; presidenciaceic@bellvitgehospital.cat), ref: PR336/22 (CSA PR4/2022)

### **Study design**

Multicenter interventional double-blinded randomized controlled trial

### **Primary study design**

Interventional

### **Study type(s)**

Prevention, Treatment

### **Health condition(s) or problem(s) studied**

Non-suicidal self-injury

### **Interventions**

This study is a randomized controlled trial (RCT) designed to evaluate the effectiveness of two App-based interventions for non-suicidal self-injury (NSSI) in adolescents and young adults. Participants will be recruited through multiple sources and screened for eligibility based on predefined inclusion and exclusion criteria. A total of 300 participants will be included: 240 with a history of Non-suicidal self-injury (NSSI) and 60 healthy controls (HC group). Participants with NSSI were recruited from clinical sites (i.e., Clinical group, N=120) as well as from the community (i.e., Subclinical group, N=120)

Participants with NSSI (both clinical and subclinical) will be randomly allocated to one of two intervention arms: (1) a specific App-based intervention (Int1) incorporating elements of Cognitive Behavioral Therapy (CBT) and Dialectical Behavior Therapy (DBT), or (2) a psychoeducational intervention (Int2). Randomization will follow an adaptive procedure, stratified by age (14-16, 17-19, and 20-24 years) and sex, ensuring balanced groups. Participants will complete an online assessment at multiple time points (baseline, post-treatment, and follow-ups). Self-report measures will include: (i) The Non-Suicidal Self-Injury

Disorder Scale (NSSIDS) to assess DSM-5 criteria for NSSI; (ii) The Inventory of Statements About Self-Injury (ISAS) to evaluate lifetime frequency and functions of NSSI.

Additionally, participants will undergo a structured diagnostic interview (Mini-International Neuropsychiatric Interview, M.I.N.I.). The Clinical group and the HC group will complete an fMRI session to assess neural correlates of NSSI.

Momentary assessments through the App will capture real-time data on emotional state, social support, and NSSI behaviors. The collected data will also be used for machine learning models to predict NSSI risk and personalize interventions.

## **Intervention Type**

Other

## **Primary outcome(s)**

Frequency of non-suicidal self-injury (NSSI) episodes and thoughts is measured using Momentary Assessments via the App (participants will report NSSI behaviors and thoughts in real-time throughout the intervention phase) and Self-Report Measures at baseline, 1 week, 5 weeks, 9 weeks (1 months follow-up) and 17 weeks (3 months follow-up).

## **Key secondary outcome(s)**

1. Emotional Regulation and Psychological Symptoms measured using self-report questionnaires at baseline, 1 week, 5 weeks, 9 weeks (1 months follow-up) and 17 weeks (3 months follow-up)
2. Emotional Regulation and Psychological Symptoms measured using momentary assessments (participants will report their emotional status through the App to track changes over time) at baseline, 1 week and 5 weeks
3. Neural pain processing and social rejection processing as biological predictors of treatment measured using Neuroimaging Measures (fMRI) at baseline
4. Engagement and Treatment Adherence using App Usage Metrics after treatment ends (ie., 5 weeks)
5. Risk of non-suicidal self-injury engagement using momentary data and neuroimaging features after ends the follow-ups

## **Completion date**

01/10/2026

# **Eligibility**

## **Key inclusion criteria**

For all participants:

1. From 14 to 24 years old
2. Provide informed consent (including parental consent for participants under 18)
3. Have access to a mobile phone.

For the control group:

1. No history of non-suicidal self-injury (NSSI), either past or present
2. Not receiving any psychological or psychiatric treatment.

For the subclinical group:

1. Have engaged in NSSI on at least five days during the last 12 months
2. Not receiving psychological or psychiatric treatment.

For the clinical group

1. Have engaged in NSSI on at least five days during the last 12 months
2. Under psychological or psychiatric treatment

**Participant type(s)**

Healthy volunteer, Patient, Population

**Healthy volunteers allowed**

No

**Age group**

Mixed

**Lower age limit**

14 years

**Upper age limit**

24 years

**Sex**

All

**Total final enrolment**

0

**Key exclusion criteria**

For participants eligible to neuroimaging:

1. Pregnancy
2. Neurological disorders
3. Claustrophobia
4. Metal implants or medical devices

For the clinical group:

1. Important clinical instability at the time of recruitment

**Date of first enrolment**

01/07/2024

**Date of final enrolment**

31/12/2025

**Locations**

**Countries of recruitment**

Spain

**Study participating centre**

**Fundació Sanitària D'Igualada**

Av. Catalunya, 11  
Igualada  
Spain  
08700

**Study participating centre**

**Hospital Sant Joan de Déu de Barcelona**

Passeig Sant Joan de Déu, 2  
Esplugues de Llobregat (Barcelona)  
Spain  
08950

**Study participating centre**

**Hospital de la Santa Creu i Sant Pau**

Carrer de Sant Quintí, 89  
Barcelona  
Spain  
08025

**Study participating centre**

**Hospital Fundació Althaia**

C/ Dr. Joan Soler, 1-3  
Manresa  
Spain  
08243

**Study participating centre**

**Hospital Universitari Mútua de Terrassa**

Plaça del Doctor Robert, 5  
Terrassa  
Spain  
08221

**Study participating centre**

**Hospital Clínic de Barcelona**

Carrer de Villarroel, 170  
Barcelona  
Spain  
08036

**Study participating centre****Consorci Corporació Sanitària Parc Taulí**

Parc del Taulí, 1

Sabadell

Spain

08208

**Study participating centre****Universitat de Barcelona**

Campus de Mundet, Universitat de Barcelona, Pg. de la Vall d'Hebron, 171,

Barcelona

Spain

08035

**Study participating centre****Universidad Jaume I**

Avinguda de Vicent Sos Baynat, s/n

Castelló de la Plana

Spain

12006

**Study participating centre****Universitat de Vic**

Carrer de la Sagrada Família, 7

Vic

Spain

08500

**Sponsor information****Organisation**

Fundació la Marató de TV3

**Funder(s)****Funder type**

Other

## Funder Name

Fundació la Marató de TV3

# Results and Publications

## Individual participant data (IPD) sharing plan

The datasets generated during and/or analysed during the current study will be available upon request from Daniel Vega (daniel.vegamo@gmail.com)

## IPD sharing plan summary

Available on request

## Study outputs

Output type	Details	Date created	Date added	Peer reviewed?	Patient-facing?
<a href="#">Protocol article</a>		27/01/2026	28/01/2026	Yes	No
<a href="#">Protocol file</a>			07/03/2025	No	No